Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Erythropoietin: molecular, cellular, and clinical biology.
The Johns Hopkins Series in Contemporary Medicine and Public Health. Erslev AJ et al, eds. Baltimore, MD, Johns Hopkins University Press, 478 p., 1991. Unique Identifier : AIDSLINE ICDB/93688707 Anonymous; No affiliation given
Abstract:
Early studies showed that the action of erythropoietin is directed at primitive, still undifferentiated cells. Subsequent studies outlined the hierarchy of red cell development from multipotential stem cells via erythroid-committed progenitor cells and erythroid precursor cells to mature red cells and showed that erythropoietin acts primarily on the progenitor cells. In the late 1970s erythropoietin was purified and isolated; later, it was shown to be a glycoprotein of 165 amino acids and containing 40% carbohydrate. The carbohydrate moiety determines in vivo viability but apparently does not affect biologic activity. Erythropoietin is employed clinically in the 'cure' of the anemia associated with chronic renal disease; it has future potential for reducing transfusion dependency and enhancing the quality of life in patients (pts) with many other kinds of anemia. This book covers basic and applied aspects of erythropoietin in chapters on the following topics: historical overview; molecular biology; structure-function relationships; regulation of erythropoietin gene expression; biogenesis of erythropoietin in vivo; renal function and oxygen sensing; the erythroid response to erythropoietin; physiology, biochemistry, and molecular biology of erythropoietin receptors; pharmacokinetics and metabolism of erythropoietin; erythropoietin in health and disease; recombinant human erythropoietin (epoetin) alfa in pts on hemodialysis (United States), in pts with renal anemia (Japan), in anemic pts on hemodialysis (Canada), in pts with predialysis renal failure, in pts with anemia of prematurity, in autologous blood donors and perisurgical pts, in pts with the anemia of chronic disease, and in pts with AIDS and AZT-induced anemia; epoetin beta in pts with end-stage renal disease (US and Japan) and in children with renal anemia (western Europe); and epoetin alfa and beta in pts on hemodialysis (western Europe) and in pts with ambulatory peritoneal dialysis.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Anemia/CHEMICALLY INDUCED/COMPLICATIONS/THERAPY Blood Donors Child Chronic Disease Clinical Trials *Erythropoietin/GENETICS/METABOLISM/THERAPEUTIC USE Gene Expression Regulation Hemodialysis Human Kidney/PHYSIOPATHOLOGY Kidney Failure/THERAPY Peritoneal Dialysis, Continuous Ambulatory Receptors, Erythropoietin/PHYSIOLOGY Recombinant Proteins/THERAPEUTIC USE Structure-Activity Relationship Zidovudine/ADVERSE EFFECTS MONOGRAPH 930530
M9350998
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
